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Worldwide there are one million women newly diagnosed with
breast cancer each year. Despite advances in early detection
through screening and family history clinics, chemotherapy and
endocrine therapy, breast cancer remains a common cause of death
with survival figures of 75% at 5 years and 60% at 10 years. While
the underlying genetic events in familial breast cancer (which
accounts for 5–10% of women with breast cancer) are attributed to
mutations in BRCA1, BRCA2, the ataxia telangiectasia gene or the
p53 gene, the genetic events for the 90% of breast cancer which is
sporadic are less clear. 
In sporadic breast cancer, allele losses (which can reveal
the location of tumour suppressor genes) from the short arm
of chromosome 17 are amongst the most frequent genetic alter-
ations observed. At least two regions on 17p have been identified
in loss of heterozygosity (LOH) or allelic imbalance studies of
paired blood and breast cancer DNA (Stack et al, 1995). One
of these regions, the p53 gene at 17p13.1, has attracted wide
attention as a tumour suppressor gene, transcription factor and
mediator of apoptosis in many types of cancer (Steele et al, 1999),
including breast cancer (Ziyaie et al, 2000). A second region,
defined by markers YNZ22 (D17S5) and 144D6 (D17S30), is
situated in band 17p13.3, 20 Mb telomeric to the p53 tumour
suppressor gene, and may contain more than one gene involved in
carcinogenesis. 
High frequencies (40–75%) of LOH (Coles et al, 1990;
Thompson et al, 1990, Stack et al, 1995) and recent international
collaborative data, including that from our group (Phelan et al,
1998), confirm the existence and clinical relevance of a tumour
suppressor gene that is distinct from p53 at 17p13.1 (Coles et al,
1990) and also displays allelic loss in a number of other human
malignancies. LOH at YNZ22 (17p13.3) appears to be an early
event in breast carcinogenesis since it is observed in ductal carci-
noma in situ (Aldaz et al, 1995) and, in ovarian cancer, precedes
p53 deletion (Phillips et al, 1996). More detailed studies of allelic
imbalance in breast cancer, using markers spanning 17p13.3 has
further refined the deletion map (Stack et al, 1995). Furthermore,
LOH at YNZ22 can occur in the absence of p53 mutation, deletion
or over-expression (Cornelis et al, 1994; Thompson et al, 1998)
suggesting both regions may be of clinical importance in sporadic
breast cancer (Thompson et al, 1998; Liscia et al, 1999). In addi-
tion, supportive evidence for the involvement of a tumour
suppressor gene, distinct from p53 on chromosome 17p, is
strengthened by the functional suppression of malignancy
observed following the transfection of chromosome 17 (but not
with chromosome 13) into breast cancer cell lines by micro cell-
mediated chromosome transfer and analysis of the resulting dele-
tions (Casey et al, 1993; Theile et al, 1995). LOH at 17p13.3 is
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also associated with an aggressive phenotype being significantly
correlated with disease recurrence and death due to breast cancer
(Thompson et al, 1998; Nagai et al, 1995). 
Recently, a candidate tumour suppressor gene HIC-1 (hyper-
methylated in cancer) has been described on chromosome 17p13.3
(Makos-Wales et al, 1995) in the region with a high level of allelic
loss in sporadic breast cancer (Phelan et al, 1998). HIC-1 was iden-
tified because of its association with a CpG-rich region or ‘CpG
island’. These islands are short and dispersed regions of DNA with
a high frequency of CpG dinucleotides relative to the genome
generally. A minor fraction (about 2%) is associated with the 5′ -
ends and hence the promoters and transcription start sites of all
housekeeping genes and of some tissue specific genes and have
thus been postulated to be sites of interaction between transcription
factors and promoters (Cross et al, 1994). The methylation state of
the base cytosine modulates the overall genomic pattern of chro-
matin organization and gene expression and the CpG dinucleotide
is the principal, but not exclusive, site of DNA methylation. 
Methylation of DNA can lead to mutation through the conver-
sion of methylated cytosine to thymidine by deamination.
Hypermethylation of normally unmethylated CpG islands has
been implicated as one alternative mechanism to chromosomal
deletion for the functional inactivation of tumour suppressor
genes. The HIC-1 gene, which is entirely encompassed within a
CpG island, is aberrantly hypermethylated and transcriptionally
inactivated in several types of human cancers including breast
cancer (Fujii et al, 1998) and may play a critical role in
mammalian development (Carter et al, 2000). Analysis of the
putative primary protein sequence suggests the gene product has
five Krupple-type Cys2-His2 zinc-fingers and an N-terminal
protein interaction domain characteristic of a subset of zinc-finger
transcription factors (Deltour et al, 1998; Guerardel et al, 1999).
Nucleotide sequence analysis has revealed a consensus p53
binding site in the 5′ flanking region 4 kb upstream from the tran-
scription start site and HIC-1 is postulated to be a potential down-
stream target of p53. Functional studies have demonstrated
activation of HIC-1 transcription by exogenous p53 in a colon
cancer cell line and transfection of the HIC-1 gene into cultured
colon cancer cells was found to suppress cell growth (Makos-
Wales, 1995). 
Thus, while mutation or LOH of tumour suppressor genes are
common events in breast cancer, silenced gene transcription asso-
ciated with hypermethylation is an alternate mechanism to chro-
mosomal deletion for the inactivation of tumour suppressor genes.
The aim of the present study was to determine the frequency of
HIC-1 transcription in a cohort of 50 breast cancers and to
compare this event with data on 17p allelic loss, p53 expression
and clinical/pathological variables including disease outcome for
the same cancers. 
MATERIALS AND METHODS 
Samples of primary breast cancer tissue were collected from 50
female Caucasian patients with a histological diagnosis of invasive
carcinoma of the breast. All 50 patients were clinically stage T1-
T3, N0-N1 and M0, previously untreated and underwent mastec-
tomy or wide local excision of the cancer. Histological type,
tumour size and nodal involvement were recorded prospectively on
the basis of pathology findings; tumour grading was not performed.
Tumour samples were handled identically and snap frozen in liquid
nitrogen prior to storage at –80˚C until analysis. Following accrual
of laboratory data, statistically significant associations were sought
between HIC-1 expression and clinical/pathological variables
using a two-tailed Fisher’s exact test. 
Extraction of RNA 
RNA was extracted as previously described (Thompson et al,
1990). Briefly, 500 mg frozen tissue was pulverized and disrupted
in 3M lithium acetate/6M urea (2 ml/100 mg tissue) and incubated
at 4˚C overnight. DNA was sheared using a Soniprep 150 ultra-
sonic disintegrator (MSE Scientific Instruments, Crawley, UK)
and the RNA recovered by centrifugation at 12000 rpm. The pellet
was resuspended in 6 ml 10 mM Tris.HCl buffer pH7 containing
0.1% sodium dodecyl sulphate, 50 µ g/ml of proteinase K
(Boehringer, Mannheim, FRG) and incubated at 37˚C for 20 min.
Protein was extracted with phenol equilibrated with 0.1 M
Tris.HCl pH7 followed by chloroform:isoamyl alcohol (24:1).
Following ethanol precipitation at –20˚C the RNA was recovered
by centrifugation, dissolved in RNase-free distilled water and
stored in aliquots at –70˚C. The quantity and purity of the RNA
was assessed by spectrophotometry. 
In addition, RNA from the human breast cancer cell lines MCF7
and MDAMB231 was also examined in this study. The cells were
grown at 37˚C in a humidified atmosphere containing 5% CO2, in
Dulbecco’s modified Eagle’s medium (Life Technologies, Paisley,
UK) containing 2 mM glutamine, 0.1 mM non-essential amino
acids, 10% fetal calf serum, 1000 U/ml penicillin and 100 µ g/ml
streptomycin. Subconfluent cultures were harvested by aspiration,
the cells washed with phosphate buffered saline and RNA isolated
with an RNA extraction kit (Qiagen, Crawley, UK) according to
the manufacturer’s instructions. 
RT-PCR 
Aliquots of RNA were digested with 10 U/ug RNase-free DNase
(Boehringer) for 1 h at 37˚C to remove contaminating genomic
DNA. An equal amount of each RNA sample was also incubated
under identical conditions in the absence of the enzyme. Both
enzyme-treated and untreated samples were purified with an RNA
purification kit (Qiagen) according to the manufacturer’s instruc-
tions. 
1–5 µ g of the RNA was reverse transcribed using oligo(dt)15 with
superscript II reverse transcriptase (Life Technologies) according to
the manufacturer’s instructions. HIC-1 transcripts were amplified in
a Hybaid Touchdown thermal cycler from the cDNA in 50 µ l
AmpliTaq Gold buffer volumes containing 10% DMSO, 1.25U
AmpliTaq Gold DNA polymerase (PE Biosystems), 200 µ m of
each dNTP, 2.5 mM MgCl2 and l µ M of each primer. Primer
sequences for HIC-1 (derived from Genbank Accession no.
L41919) (Table 1) were designed to amplify a 242bp fragment from
exon 2 of the HIC-1 gene. To activate the AmpliTaq Gold DNA
polymerase the reaction mixture was incubated at 95˚C for 12 min.
Amplification conditions were 35 cycles of 95˚C for 1 min (denatu-
ration) and 72˚C for 1 min (annealing and extension). PCR was also
performed using primers specific for MDM2 and β -Actin as positive
control reactions for successful cDNA synthesis (Table 1). MDM2
transcripts were amplified in a final volume of 50 µ l AmpliTaq
buffer containing 1.25U AmpliTaq (PE Biosystems), 200 µ M of
each dNTP, 1.5 mM MgCl2, and 1 µ M of each primer.
Amplification conditions were 95˚C for 5 min (initial denaturation)
followed by 35 cycles of 95˚C for 1 min (denaturation), 65˚C for1880 G Nicoll et al 
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1 min (annealing) and 72˚C for 1 min (extension). β -Actin tran-
scripts were produced using RT-PCR control amplimers (Clontech)
according to the manufacturer’s instructions. Following amplifica-
tion, 5 µ l of DNA loading buffer (bromophenol blue in 50% w/v
glycerol) was added to each PCR reaction, PCR products were
resolved on 1% agarose gels, containing 0.5 µ g/ml ethidium
bromide and visualized under UV illumination. A 1kb DNA ladder
was used as size standards. PCR positive controls included the
amplification of HIC-1 from genomic tonsil DNA, MDM2 from
plasmid CMX-mdm2 containing full length human MDM2 cDNA
(gifted from Christine Blattner) and human β actin control
(Clontech). Negative controls consisted of all the components of the
PCR excluding target sequences. 
p53 expression and 17p13.3 allele loss (LOH) 
From the same samples used for RT-PCR studies, total RNA for
the 50 breast cancers was used for northern blots and p53 mRNA
expression detected using the 2.1 kb cDNA clone php53Bam, the
filters stripped then reprobed for alpha actin as internal control as
previously described (Thompson et al, 1990). DNA was extracted
from cancer tissue immediately adjacent to that used for the RNA
studies and from the patient’s venous blood lymphocytes
(Thompson et al, 1990). Lymphocytes were used in preference to
apparently normal breast tissue given the adverse cosmetic impact
excising further breast tissue could have on breast conservation
and the possibility of additional foci of cancer in mastectomy spec-
imens. Allele loss (using a cut-off of 50% band strength) was
detected using blood/tumour pairs for the 50 patients using
Southern blots probed with YNZ22 which maps to 17p13.3 as
previously described (Thompson et al, 1990). 
Reactivation of HIC-1 expression in MDAMB231 
MDAMB231 cells were seeded at 1 × 105 per 75-mm2 flask in
phenol red free Minimum Essential Medium (GibcoBRL)
containing 2 mM glutamine, 10% fetal calf serum, 1000 U/ml
penicillin and 100 µ g/ml streptomycin. After 24 h the cells were
incubated with freshly prepared medium containing 3 × 10–7M 
5-aza-2′ -deoxycytidine (DeoxyC); (Sigma). DeoxyC-containing
medium was replaced on days 5 and 8. The cells were harvested on
day 10 for RNA extraction and RT-PCR as described above. 
RESULTS 
HIC-1 expression was detected in the MCF7 cell line and in 7/50
breast cancers (14%) by RT-PCR, but despite positive actin and
MDM2 controls, no expression was detected in the MDAMB231
cell line nor in 43/50 (86%) of the cancers (Figure 1). The HIC-1
RT-PCR product was sequenced and the published HIC-1
sequence confirmed (data not shown). In the MDAMB231 cell
line, consititutional expression of beta actin and mdm2 genes was
detected (Figure 2A) indicating the successful transcription of
Table 1 Primer sets for HIC-1, MDM2 and β actin expression studies by RT-PCR 
Primer set Sense primer Antisense primer Size bp 
HIC-1 ATGGTGAGCCCGGCCGTGTTCC TAGCCGCCGCCGCCGCCGCCGC 242 
MDM2 GGGAGATATGTTGTGAAA AGATTCAACTTCAAATTC 152 
β actin ATCTGGCACCACACCTTCTACA CGTCATACTCCTGCTTGCTGATCC 838 
ATGAGCTGCG ACATCTGC 
+ − + − + − + −
300 bp
123456 789 1 0 1 1 1 2
+ − + − + − + −
300 bp
123456789 1 0 1 1 1 2
+ − + − + − + −
300 bp




Figure 1 HIC-1 expression in breast cancer cell lines MCF7, MDAMB231
and a human breast cancer. RT-PCR was used to detect HIC-1 mRNA
expression (242 bp) and MDM2 expression (152 bp) in: (A) MCF7. (B) MDA-
MB-231. (C) Breast cancer (patient number 38). +/– indicate whether reverse
transcriptase (RT) was added to (+) or omitted from (–) the reaction. Lane
1–6 HIC-1 RT-PCR, Lane 7–12 MDM2 RT-PCR. Lane 1: DNase treated.
Lane 2: DNase treated no RT. Lane 3: no DNase. Lane 4: no DNase, no RT.
Lane 5: negative control for PCR reaction. Lane 6: positive control. Lane 7:
DNase treated. Lane 8: DNase, no RT. Lne 9: no DNase. Lane 10: no









Figure 2 RT-PCR was used to detect actin mRNA (838 bp) expression in
MDAMB231 (Figure 2A) and HIC-1 mRNA expression in DeoxyC treated
MDAMB231 (Figure 2B): A Beta actin expression in MDAMB231. Lane 1:
DNase treated. Lane 2: DNase treated no RT. Lane 3: negative control for
PCR reaction. Lane 4: positive control. +/– indicate whether reverse
transcriptase was added to (+) or omitted from (–) the reaction. 
B Restoration of HIC-1 expression in MDAMB231. Lane 1: DNase treated; 
5-aza-2′ -deoxycytidine treated-MDAMB231: Lane 2: negative control for
PCR reaction. Lane 3: positive control HIC-1 and prognosis in breast cancer 1881
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cDNA. Furthermore, HIC-1 expression was restored following
treatment with the demethylating drug DeoxyC (Figure 2B). p53
mRNA expression was detected in 32/50 (64%) cancers, YNZ22
loss of heterozygosity (LOH) demonstrated in 21/50 (42%) with
16/50 (32%) patients constitutionally homozygous (Thompson
et al, 1998). 
Among the seven cancers where HIC-1 expression was detected
using RT-PCR, 5/7 (71%) had detectable p53 expression which
was wild type, (Thompson et al, 1992) (Table 2A) and 4/7 had
YNZ22 LOH (3 were homozygous) (Table 2B). For the 43/50
cancers which tested negative for HIC-1 expression, 25/43 were
positive for p53 expression and 17/43 (34%) had YNZ22 LOH
(13 no loss, 13 homozygous). 
All seven patients in whom cancer HIC-1 expression was
detected were alive after 8 years follow-up (Table 3); 3/7 were
oestrogen receptor (ER) positive and 1/7 was histologically node
positive. For the remaining 43 patients in whom HIC-1 expression
could not be detected, 28/43 (65%) were ER positive, 23/43 (54%)
were node positive and 23/43 (54%) were alive without disease
recurrence after 8 years follow-up (Table 3). 
HIC-1 expression (detected in seven cancers) was associated with
YNZ22 LOH (P = 0.015, two-tailed Fisher’s exact test), absence of
node metastasis at diagnosis (P = 0.045) and all seven patients were
alive without recurrence at 8 years follow-up (P = 0.04). There was
no significant association between HIC-1 expression and oestrogen
receptor status, histological tumour size or histological type (all the
cancers studied were ductal carcinoma of no special type). 
DISCUSSION 
Following the demonstration in this study (using reverse transcrip-
tion polymerase chain reaction, RT-PCR) that the hormone-
responsive cell line MCF7 expressed HIC-1 transcripts and
wild-type p53 but that the hormone receptor-negative, MDA-MB-
231 cell line which expresses mutant p53 did not transcribe HIC-1,
we have examined a pilot series of 50 sporadic breast cancers
for HIC-1 transcription and compared this with p53 mRNA
expression, YNZ22 allele loss, node status, oestrogen receptor
expression and disease recurrence. In addition, we have demon-
strated that HIC-1 expression can be restored by the use of a
demethylating drug, DeoxyC, in a breast cancer cell line without
detectable HIC-1 expression prior to treatment. 
The MCF7 HIC-1 expression data contrasts with the initial
study of HIC-1 and breast cancer which failed to identify HIC-1
expression in MCF7 by the RNase protection assay (Makos-Wales
et al, 1995); however, in keeping with our current report, subse-
quent studies have suggested HIC-1 is expressed in MCF7
(Fujii et al, 1998). 
HIC-1 transcripts were demonstrated in only 7/50 (14%)
cancers despite positive internal controls for MDM2 and actin
demonstrating successful RT-PCR from the RNA of all 50 cancers.
This concords with the only published series of 39 breast cancers
(Fujii et al, 1998) where, using an alternative experimental
approach, HIC-1 appeared to be inactive in 67% of cancers. 
For the first time we have identified an association between
retained HIC1 expression and absence of node metastasis at diag-
nosis (P = 0.045); indeed, all seven patients were alive without
recurrence at 8 years follow-up (P= 0.04). In the present series there
was no significant association between HIC-1 expression and
oestrogen receptor status (there is no clinical data cited by Fujii et al,
1998). In the present study we have also shown that HIC-1 expres-
sion (seven cancers) was associated with YNZ22 LOH (P = 0.015,
two-tailed Fisher’s exact test) a result which concurs with that previ-
ously reported (Fujii et al, 1998). Given the link between YNZ22
LOH and poor prognosis in breast cancer (Thompson et al, 1998;
Liscia et al, 1999) one might expect HIC-1 expression would corre-
late with poor prognosis. These differing associations suggest that
HIC-1 may be distinct from a second gene involved in breast cancer
marked by YNZ22. In addition HIC-1 may protect against the dele-
terious effects of YNZ22 LOH. Moreover, in our series, HIC-1
expression was not associated with p53 expression or with p53
mutation (Thompson et al, 1998) although activation of HIC-1
expression by p53 has been reported in colorectal cancer cell lines
(Makos-Wales et al, 1995) and p53 mutation has been linked to
HIC-1 methylation in four cancers (Fujii et al, 1998). 
Regional DNA hypermethylation at 17p13.3 has been shown to
precede 17p structural changes and is thus an early event in the
progression of renal tumours (Makos et al, 1993) but, conversely,
is a late event in haemopoietic malignancies (Issa et al, 1997). In
breast cancer the hypermethylation of HIC-1 has been demon-
strated in cultured neoplastic cells (Makos-Wales et al, 1995)
although other mechanisms of HIC-1 inactivation such as muta-
tion may occur. 
The failure to detect HIC-1 transcripts in MCF7 cells in an
earlier study (Makos Wales et al, 1995) may be attributable to their
use of a less sensitive assay (RNase protection) or a consequence
of phenotypic divergence of the cell lines maintained under
separate culture conditions in different laboratories. It has been
reported that one HIC-1 allele is methylated in normal breast
epithelium and that such hemimethylation predisposes to
increased risk of breast cancer through mutation of the other allele
(Fujii et al, 1998). In contrast, methylation of the HIC-1 CpG
Table 2 A HIC-1 expression, p53 expression and B YNZ 22 allele loss 
A p53mRNA expression 
Yes No 
HIC-1 expression yes 5 2 
HIC-1 expression no 25 18 
B YNZ22 
Allele No  allele Homozygous
loss loss 
HIC-1 expression yes 4 0 3 
HIC-1 expression no 17 13 13 
Table 3 HIC-1 expression and clinical/pathological parameters 
ER ER Node Node Disease 
positive negative positive negative recurrence 
HIC-1 Yes (n = 7) 3  4 1 6 0 
Expression No (n = 43) 28 15 23 20  20island extends to a sequence between the intron 2 and exon 3 junc-
tion in normal haemopoietic cells but occurs beyond this boundary
in newly diagnosed acute myeloid leukaemias (Melki et al, 1999).
Thus the extent of methylation, as opposed to methylation per se
may be a more reliable indicator of gene inactivation. In the
present study we have investigated breast cancer RNA directly by
RT-PCR for evidence of HIC1 transcription. 
Promoter-associated CpG islands can be chemically modified by
methylation of cytosine that prevents expression of the gene. This
could be of particular relevance in breast cancer as oestrogen
receptor genes may also become hypermethylated (Issa et al, 1997;
Li et al, 1998), a potential mechanism for resistance of oestrogen
receptor positive breast cancers to endocrine therapy, and gene
methylation of the oesotrogen receptor increases with age (Li et al,
1998), as does breast cancer. Thus, altering the methylation status of
cancer cells through pharmacological inhibition of DNA methyl-
transferase with resultant DNA demethylation (Issa et al, 1997)
offers a novel therapeutic approach to reactivating tumour
suppressor function of genes such as HIC-1, as we have demon-
strated here with MDAMB231, but may also be relevant to reacti-
vating the function of what are currently therapeutically useful
genes such as oestrogen receptor. Indeed, the demethylating effects
on gene expression (and hence putative reactivation) by the drug
5 aza-2′ -deoxycytidine are undergoing further study in our laborato-
ries. Immunohistochemical analysis of 5 aza-2′ - deoxycytidine
treated MDAMB231 cells has demonstrated an increased expres-
sion of p53, the proto-oncogene erbB2, and the oestrogen respon-
sive protein pS2 as well as re-expression of HIC-1 (data not shown). 
Thus, HIC-1 is a prime candidate gene in the development of
sporadic breast cancer since it is located in a chromosomal region of
17p distinct from p53 that frequently undergoes LOH. However, the
relative contributions of mutation, deletion and methylation leading
to HIC-1 inactivation in breast cancer remain unclear. In addition,
the putative role for HIC-1 as a tumour suppressor gene, the rela-
tionship to p53 and the clinical importance of HIC-1 (with potential
for therapeutic attack) in breast cancer require further elucidation.
Our data suggest that events on chromosome 17p13 including
HIC-1 and p53 may be of more interest than hitherto expected. 
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